Immunome (IMNM) News Today $8.50 -0.35 (-3.95%) Closing price 04:00 PM EasternExtended Trading$8.68 +0.18 (+2.06%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Target Price at $25.33May 5 at 2:15 AM | americanbankingnews.comPrice T Rowe Associates Inc. MD Has $24.24 Million Stock Holdings in Immunome, Inc. (NASDAQ:IMNM)Price T Rowe Associates Inc. MD raised its stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 12.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,282,754 shares of the company's stock after buying an addiMay 4 at 4:10 AM | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of "Buy" from BrokeragesShares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have been given an average rating of "Buy" by the six research firms that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price tMay 2 at 4:24 AM | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Stock Holdings Raised by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. raised its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 127.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 500,000 shares of the company's stock after purchasing an additional 280,000 shares during the period. AdageMay 1, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Sells 262,059 Shares of Immunome, Inc. (NASDAQ:IMNM)T. Rowe Price Investment Management Inc. cut its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,499,954 shares of the company's stock after selling 262,059 shares during the period. T. Rowe PrApril 28, 2025 | marketbeat.comRenaissance Technologies LLC Purchases 304,700 Shares of Immunome, Inc. (NASDAQ:IMNM)Renaissance Technologies LLC increased its position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 2,696.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 316,000 shares of the cApril 26, 2025 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Stake Cut by Marshall Wace LLPMarshall Wace LLP decreased its holdings in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 17.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,216,182 shares of the company's stock after sellinApril 23, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 624,045 Shares of Immunome, Inc. (NASDAQ:IMNM)JPMorgan Chase & Co. grew its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 2,540.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 648,610 shares of the company's stock after acquiring an addApril 19, 2025 | marketbeat.comImmunome: Transformed Pipeline Offers Multiple CatalystsApril 17, 2025 | seekingalpha.comVanguard Group Inc. Sells 128,130 Shares of Immunome, Inc. (NASDAQ:IMNM)Vanguard Group Inc. reduced its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 4.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,003,438 shares of the company's stock after selling 128,130 sharesApril 15, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Reaches New 1-Year Low - Time to Sell?Immunome (NASDAQ:IMNM) Hits New 12-Month Low - Time to Sell?April 9, 2025 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Buy" by BrokeragesImmunome, Inc. (NASDAQ:IMNM - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have issued a report oApril 7, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Stock Price Up 4.4% - Time to Buy?Immunome (NASDAQ:IMNM) Stock Price Up 4.4% - What's Next?April 4, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Coverage Initiated by Analysts at Lake Street CapitalLake Street Capital assumed coverage on shares of Immunome in a research report on Wednesday. They issued a "buy" rating and a $23.00 price objective on the stock.April 4, 2025 | marketbeat.comImmunome initiated with a Buy at Lake StreetApril 4, 2025 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Stock Price Down 6.7% - What's Next?Immunome (NASDAQ:IMNM) Shares Down 6.7% - Here's WhyApril 3, 2025 | marketbeat.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2025 | businesswire.comLake Street Initiates Coverage of Immunome (IMNM) with Buy RecommendationApril 3, 2025 | msn.comClay Siegall Bought 20% More Shares In ImmunomeApril 2, 2025 | finance.yahoo.comImmunome (NASDAQ:IMNM) Sets New 1-Year Low - Here's What HappenedImmunome (NASDAQ:IMNM) Hits New 12-Month Low - Here's WhyApril 1, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Up 4.4% on Insider Buying ActivityImmunome (NASDAQ:IMNM) Stock Price Up 4.4% on Insider Buying ActivityMarch 28, 2025 | marketbeat.comImmunome CEO buys $999.5K in common stockMarch 28, 2025 | markets.businessinsider.comClay B. Siegall Buys 137,100 Shares of Immunome, Inc. (NASDAQ:IMNM) StockImmunome, Inc. (NASDAQ:IMNM - Get Free Report) CEO Clay B. Siegall bought 137,100 shares of the stock in a transaction on Wednesday, March 26th. The stock was purchased at an average price of $7.29 per share, for a total transaction of $999,459.00. Following the purchase, the chief executive officer now directly owns 806,736 shares of the company's stock, valued at approximately $5,881,105.44. This represents a 20.47 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.March 27, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Gap Up Following Insider Buying ActivityImmunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying ActivityMarch 27, 2025 | marketbeat.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) CEO Purchases 137,100 Shares of StockMarch 27, 2025 | insidertrades.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) Director Acquires 7,000 Shares of StockImmunome, Inc. (NASDAQ:IMNM - Get Free Report) Director Jean Jacques Bienaime bought 7,000 shares of the company's stock in a transaction dated Monday, March 24th. The stock was purchased at an average cost of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the acquisition, the director now owns 23,615 shares in the company, valued at $193,879.15. This trade represents a 42.13 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.March 26, 2025 | marketbeat.comPhilip Tsai Buys 12,300 Shares of Immunome, Inc. (NASDAQ:IMNM) StockImmunome, Inc. (NASDAQ:IMNM - Get Free Report) CTO Philip Tsai bought 12,300 shares of the stock in a transaction on Monday, March 24th. The shares were acquired at an average cost of $8.42 per share, with a total value of $103,566.00. Following the acquisition, the chief technology officer now directly owns 33,300 shares in the company, valued at approximately $280,386. This trade represents a 58.57 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.March 26, 2025 | marketbeat.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) Director Buys 7,000 Shares of StockMarch 26, 2025 | insidertrades.comVirtu Financial LLC Makes New $486,000 Investment in Immunome, Inc. (NASDAQ:IMNM)Virtu Financial LLC bought a new position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 45,743 shares of the company's stock, valued at approximMarch 26, 2025 | marketbeat.comImmunome CTO buys $103.6K in common stockMarch 26, 2025 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Reaches New 52-Week Low - Should You Sell?Immunome (NASDAQ:IMNM) Reaches New 12-Month Low - Time to Sell?March 25, 2025 | marketbeat.comWedbush Has Positive Estimate for Immunome Q1 EarningsImmunome, Inc. (NASDAQ:IMNM - Free Report) - Investment analysts at Wedbush raised their Q1 2025 earnings estimates for Immunome in a research report issued on Wednesday, March 19th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.51) per share for the quarter, up fromMarch 24, 2025 | marketbeat.comWedbush Keeps Their Buy Rating on Immunome (IMNM)March 21, 2025 | markets.businessinsider.comImmunome (IMNM) Receives a Buy from Piper SandlerMarch 21, 2025 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Receives "Outperform" Rating from WedbushWedbush restated an "outperform" rating and set a $33.00 target price on shares of Immunome in a research report on Thursday.March 21, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Given "Overweight" Rating at StephensStephens reaffirmed an "overweight" rating and set a $30.00 price objective on shares of Immunome in a research note on Thursday.March 21, 2025 | marketbeat.comImmunome price target lowered to $25 from $35 at GuggenheimMarch 21, 2025 | markets.businessinsider.comGuggenheim Has Lowered Expectations for Immunome (NASDAQ:IMNM) Stock PriceGuggenheim lowered their target price on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday.March 21, 2025 | marketbeat.comImmunome’s 2024 Financial Results and Pipeline ProgressMarch 21, 2025 | tipranks.comImmunome (NASDAQ:IMNM) Issues Quarterly Earnings Results, Misses Expectations By $0.16 EPSImmunome (NASDAQ:IMNM - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%.March 20, 2025 | marketbeat.comImmunome reports FY24 revenue $9.04M, consensus $9.41MMarch 20, 2025 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Hits New 52-Week Low - Here's What HappenedImmunome (NASDAQ:IMNM) Hits New 12-Month Low - Here's What HappenedMarch 20, 2025 | marketbeat.comImmunome (IMNM) Expected to Announce Quarterly Earnings on ThursdayImmunome (NASDAQ:IMNM) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comWith 59% ownership of the shares, Immunome, Inc. (NASDAQ:IMNM) is heavily dominated by institutional ownersMarch 17, 2025 | finance.yahoo.comLifesci Capital Estimates Immunome FY2024 EarningsImmunome, Inc. (NASDAQ:IMNM - Free Report) - Equities research analysts at Lifesci Capital issued their FY2024 EPS estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu forecasts that the company will earn ($1.83) per share for the yMarch 15, 2025 | marketbeat.comQ1 Earnings Estimate for Immunome Issued By Lifesci CapitalImmunome, Inc. (NASDAQ:IMNM - Free Report) - Stock analysts at Lifesci Capital issued their Q1 2025 EPS estimates for shares of Immunome in a report issued on Tuesday, March 11th. Lifesci Capital analyst C. Zhu forecasts that the company will earn ($0.61) per share for the quarter. Lifesci CapitaMarch 14, 2025 | marketbeat.comLifeSci Capital Initiates Coverage of Immunome (IMNM) with Outperform RecommendationMarch 12, 2025 | msn.comImmunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of "Buy" by BrokeragesImmunome, Inc. (NASDAQ:IMNM - Get Free Report) has earned a consensus recommendation of "Buy" from the six analysts that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokeragesMarch 12, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Coverage Initiated by Analysts at Lifesci CapitalLifesci Capital started coverage on shares of Immunome in a report on Tuesday. They set an "outperform" rating and a $20.00 price objective for the company.March 12, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Hits New 12-Month Low - Time to Sell?Immunome (NASDAQ:IMNM) Reaches New 12-Month Low - Should You Sell?March 11, 2025 | marketbeat.com Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address IMNM Media Mentions By Week IMNM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMNM News Sentiment▼1.280.72▲Average Medical News Sentiment IMNM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMNM Articles This Week▼44▲IMNM Articles Average Week Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AKRO News Today VKTX News Today XENE News Today CPRX News Today MOR News Today PTGX News Today HCM News Today IMVT News Today APLS News Today MLTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMNM) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredU.S. Stock Market Now on Verge of CollapseThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMNM Stock Free IMNM Stock Alerts